Stephen E. Zale
53Patents
28h-index
45Co-inventors
88Inventor score
Filing activity: Jul 27, 1992 → Jun 8, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5916597A | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent | Human Necessities | 241 | Expired |
| US6495164B1 | Preparation of injectable suspensions having improved injectability | Human Necessities | 163 | Expired |
| US8613951B2 | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same | Emerging Cross-Sectional Technologies | 136 | Active |
| US8734846B2 | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles | Human Necessities | 130 | Active |
| US8709483B2 | System for targeted delivery of therapeutic agents | Human Necessities | 117 | Active |
| US8603501B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 107 | Active |
| US8617608B2 | Drug loaded polymeric nanoparticles and methods of making and using same | Emerging Cross-Sectional Technologies | 105 | Active |
| US8603500B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 105 | Active |
| US8603499B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 105 | Active |
| US8613954B2 | Drug loaded polymeric nanoparticles and methods of making and using same | Emerging Cross-Sectional Technologies | 100 | Active |
| US5674534A | Composition for sustained release of non-aggregated erythropoietin | Emerging Cross-Sectional Technologies | 93 | Expired |
| US5716644A | Composition for sustained release of non-aggregated erythropoietin | Human Necessities | 92 | Expired |
| US8246968B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 89 | Active |
| US8563041B2 | Therapeutic particles suitable for parenteral administration and methods of making and using same | Performing Operations; Transporting | 83 | Active |
| US8603534B2 | Drug loaded polymeric nanoparticles and methods of making and using same | Emerging Cross-Sectional Technologies | 83 | Active |
| US8603535B2 | Stable formulations for lyophilizing therapeutic particles | Emerging Cross-Sectional Technologies | 80 | Active |
| US8637083B2 | Stable formulations for lyophilizing therapeutic particles | Emerging Cross-Sectional Technologies | 76 | Active |
| US5683916A | Membrane affinity apparatus and purification methods related thereto | Emerging Cross-Sectional Technologies | 74 | Expired |
| US6667061B2 | Preparation of injectable suspensions having improved injectability | Human Necessities | 67 | Expired |
| US8211473B2 | Stable formulations for lyophilizing therapeutic particles | Emerging Cross-Sectional Technologies | 62 | Active |
| US8206747B2 | Drug loaded polymeric nanoparticles and methods of making and using same | Emerging Cross-Sectional Technologies | 62 | Active |
| US8273363B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 57 | Active |
| US8236330B2 | Cancer cell targeting using nanoparticles | Emerging Cross-Sectional Technologies | 55 | Active |
| US8318211B2 | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same | Human Necessities | 44 | Active |
| US8318208B1 | Drug loaded polymeric nanoparticles and methods of making and using same | Emerging Cross-Sectional Technologies | 43 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.